(Q84276325)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21641953%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21641953%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

Dmitri Smirnov

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21641953%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Joshua J Schmidt

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21641953%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

John T Capecchi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21641953%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Paul D Wightman

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21641953%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

1 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21641953%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21641953%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21641953%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21641953%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

5434-5442

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21641953%20AND%20SRC:MED&resulttype=core&format=json

Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Recent advances in vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Emerging drugs for actinic keratosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

A phase II dose-ranging study of topical resiquimod to treat actinic keratosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Adjuvant activities of immune response modifier R-848: comparison with CpG ODN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Intra-colonic administration of the TLR7 agonist R-848 induces an acute local and systemic inflammation in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.061

10.1016/J.VACCINE.2011.05.061

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21641953%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference